A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Peginterferon Alfa 2a (Pegasys) And Ribavirin (Copegus) With And Without PF-00868554 In Subjects Chronically Infected With Hepatitis C Virus.
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2013
At a glance
- Drugs Filibuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 22 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
- 15 Apr 2010 Results were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).
- 09 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History